They moved significantly towards regenerative medicine applications.

for the first time in the world, iPS cells were supposed to be used to treat human disease. The 26th, the national examination on clinical research program of incurable disease, age-related macular degeneration of the eye end to substantially, transplant surgery is performed to next year. IPS cells, began to move significantly towards regenerative medicine applications in the seven years from announcement produced in mice.
Team in February, Takahashi project leaders (Kobe) RIKEN Center for Developmental Biology is applied research. IPS cells that are artificially created or not the abnormal behavior after transplantation, examination committee, discussed intensively for safety. After a debate three times, was approved with the conditions such as the submission of additional data about the iPS cell production. After reporting on science and technology subcommittee of the Health Science Council to be held in mid-July, written opinion of formal acknowledgment is sent from the thick labor minister.
Subjects, patients with age-related macular degeneration severe. The type called (effusion ye) effusion type common in Japanese, such as unwanted blood vessels can be organized under the retina called "pigment epithelium", view missed or retina is pushed up, I will cause blindness. Clinical research I Now you are ready to start. I think hurdle that various lie ahead, but I want you out the results.


ｉＰＳ細胞が世界で初めて、人の病気の治療に使われることになった。２６日、目の難病・加齢黄斑変性の臨床研究計画に関する国の審査が実質的に終わり、来年にも移植手術が行われる。マウスでの作製発表から７年でｉＰＳ細胞は、再生医療応用に向けて大きく動き出した。
　研究は２月、理化学研究所発生・再生科学総合研究センター（神戸市）の高橋プロジェクトリーダーらのチームが申請した。審査委は、人工的につくられるｉＰＳ細胞が移植後に異常な振る舞いをしないか、安全性について集中的に議論。３回にわたる議論を経て、ｉＰＳ細胞作製に関する追加データの提出などの条件をつけて承認した。７月半ばに開かれる厚生科学審議会の科学技術部会に報告後、厚労相から正式な了承の意見書が通知される。
　対象は、重症の加齢黄斑変性の患者。日本人に多い滲出型（しんしゅつがた）と呼ばれるタイプでは、網膜の下にある「色素上皮」という組織に不要な血管などができ、網膜が押し上げられて視野が欠けたり、失明したりする。 いよいよ臨床研究が始まりますね。様々なハードルが待ち受けていると思いますが結果を出してほしいですね。